PIL in High Court seeks Remdesivir makers be allowed to sell it in domestic market

The anti-viral drug has been witnessing a shortage in India in the midst of a new Covid-19 wave

The Delhi High Court Monday asked the Centre and various pharma majors to respond to a PIL seeking that all drug firms making Remdesivir, used in Covid-19 treatment, be allowed to sell it in the domestic market.

A bench of Chief Justice D N Patel and Justice Jasmeet Singh issued notice to the Health Ministry, Central Drugs Standard Control Organisation, Director General of Foreign Trade and various pharma companies, like Cipla, Zydus and Cadila, seeking their stand on the plea which claims only a handful of such firms are allowed to sell the medicine in the domestic market.

Read more: Increase allocation of Remdesivir to Maharashtra: Bombay HC tells Centre

The remaining companies were involved in manufacturing the drug for export, petitioner Dincur Bajaj said, adding that since export of Remdesivir has been banned by the Centre, the companies which were producing it for export be permitted to manufacture and sell it in the domestic market.

Bajaj, who is a lawyer and the Joint Secretary of the Delhi High Court Bar Association, has claimed that there are more than 25 companies in India which manufacture the medicine, but only six to eight of them are permitted to sell it in the domestic market and the rest were producing it for exports alone.

The plea, filed through advocate Amit Saxena and Imran Ali, has said, "It is pertinent to mention that the scarcity of Remdesivir is causing its extensive black-marketing and the black marketers are charging prices up to Rs 1,00,000 per vial, due to its non-availability."